Log In
BCIQ
Print this Print this
 

TG1050

  Manage Alerts
Collapse Summary General Information
Company Transgene S.A.
DescriptionAdenovirus serotype 5 (Ad5) vector vaccine carrying modified HBV polymerase, hepatitis B core antigen (HBcAg) and 3 surface antigen (HBsAg) domains
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: Viral vaccine
Latest Stage of DevelopmentPhase I
Standard IndicationHepatitis B virus (HBV)
Indication DetailsPrevent HBV infection; Treat chronic HBV infection
Regulatory Designation
PartnerTasly Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$9.7M

$9.7M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/06/2012

$9.7M

$9.7M

0

Get a free BioCentury trial today